<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T10:04:26Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:10483320" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:10483320</identifier>
        <datestamp>2023-09-08</datestamp>
        <setSpec>jamasd</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" dtd-version="1.3" xml:lang="en" article-type="research-article">
          <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
            <restricted-by>pmc</restricted-by>
          </processing-meta>
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">JAMA Netw Open</journal-id>
              <journal-id journal-id-type="iso-abbrev">JAMA Netw Open</journal-id>
              <journal-title-group>
                <journal-title>JAMA Network Open</journal-title>
              </journal-title-group>
              <issn pub-type="epub">2574-3805</issn>
              <publisher>
                <publisher-name>American Medical Association</publisher-name>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC10483320</article-id>
              <article-id pub-id-type="pmcid">PMC10483320</article-id>
              <article-id pub-id-type="pmc-uid">10483320</article-id>
              <article-id pub-id-type="pmid">37672269</article-id>
              <article-id pub-id-type="pmid">37672269</article-id>
              <article-id pub-id-type="doi">10.1001/jamanetworkopen.2023.32579</article-id>
              <article-id pub-id-type="publisher-id">zoi230944</article-id>
              <article-categories>
                <subj-group subj-group-type="category" specific-use="electronic">
                  <subject>Research</subject>
                </subj-group>
                <subj-group subj-group-type="heading">
                  <subject>Original Investigation</subject>
                </subj-group>
                <subj-group subj-group-type="online-only">
                  <subject>Online Only</subject>
                </subj-group>
                <subj-group subj-group-type="subject-area">
                  <subject>Oncology</subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Antidepressant Use and Mortality Among Patients With Hepatocellular Carcinoma</article-title>
                <alt-title alt-title-type="headline">Antidepressant Use and Mortality Among Patients With Hepatocellular Carcinoma</alt-title>
                <alt-title alt-title-type="running-head">Antidepressant Use and Mortality Among Patients With Hepatocellular Carcinoma</alt-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author">
                  <name>
                    <surname>Huang</surname>
                    <given-names>Kuan-Lun</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="zoi230944aff1" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                  <xref rid="zoi230944aff2" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Chen</surname>
                    <given-names>Yi-Lung</given-names>
                  </name>
                  <degrees>PhD</degrees>
                  <xref rid="zoi230944aff2" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                  <xref rid="zoi230944aff3" ref-type="aff">
                    <sup>3</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Stewart</surname>
                    <given-names>Robert</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="zoi230944aff4" ref-type="aff">
                    <sup>4</sup>
                  </xref>
                  <xref rid="zoi230944aff5" ref-type="aff">
                    <sup>5</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author" corresp="yes">
                  <name>
                    <surname>Chen</surname>
                    <given-names>Vincent Chin-Hung</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <degrees>PhD</degrees>
                  <xref rid="zoi230944aff6" ref-type="aff">
                    <sup>6</sup>
                  </xref>
                  <xref rid="zoi230944aff7" ref-type="aff">
                    <sup>7</sup>
                  </xref>
                </contrib>
              </contrib-group>
              <aff id="zoi230944aff1"><label>1</label>Tsaotun Psychiatric Center, Ministry of Health and Welfare, Nantou, Taiwan</aff>
              <aff id="zoi230944aff2"><label>2</label>Department of Healthcare Administration, College of Medical and Health Science, Asia University, Taichung, Taiwan</aff>
              <aff id="zoi230944aff3"><label>3</label>Department of Psychology, College of Medical and Health Science, Asia University, Taichung, Taiwan</aff>
              <aff id="zoi230944aff4"><label>4</label>Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, London, United Kingdom</aff>
              <aff id="zoi230944aff5"><label>5</label>South London and Maudsley National Health Services Foundation Trust, London, United Kingdom</aff>
              <aff id="zoi230944aff6"><label>6</label>Department of Psychiatry, Chiayi Chang Gung Memorial Hospital, Chiayi, Taiwan</aff>
              <aff id="zoi230944aff7"><label>7</label>School of Medicine, Chang Gung University, Taoyuan, Taiwan</aff>
              <author-notes>
                <title>Article Information</title>
                <p><bold>Accepted for Publication:</bold> July 31, 2023.</p>
                <p content-type="published-online"><bold>Published:</bold> September 6, 2023. <?xpp bx;1?>doi:<uri content-type="doi">10.1001/jamanetworkopen.2023.32579</uri></p>
                <p content-type="open-access-note"><bold>Open Access:</bold> This is an open access article distributed under the terms of the <ext-link xlink:href="https://jamanetwork.com/pages/cc-by-license-permissions" ext-link-type="uri">CC-BY License</ext-link>. © 2023 Huang KL et al. <italic>JAMA Network Open</italic>.</p>
                <corresp id="zoi230944cor1"><bold>Corresponding Author:</bold> Vincent Chin-Hung Chen, MD, PhD, Department of Psychiatry, School of Medicine, Chang Gung Memorial Hospital, Chang Gung University, No. 6, W Sec, Jiapu Road, Puzi City, Chiayi County, Taiwan 613 (<email xlink:href="cch1966@gmail.com">cch1966@gmail.com</email>).</corresp>
                <p content-type="author-contributions"><bold>Author Contributions:</bold> Dr Y. Chen had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Drs Huang and Y.-L. Chen contributed equally to this article.</p>
                <p><italic>Concept and design:</italic> All authors.</p>
                <p><italic>Acquisition, analysis, or interpretation of data:</italic> Huang, Y. Chen, V. Chen.</p>
                <p><italic>Drafting of the manuscript:</italic> Huang, Y. Chen, V. Chen.</p>
                <p><italic>Critical review of the manuscript for important intellectual content:</italic> All authors.</p>
                <p><italic>Statistical analysis:</italic> Y. Chen.</p>
                <p><italic>Obtained funding:</italic> Huang.</p>
                <p><italic>Administrative, technical, or material support:</italic> Huang, Y. Chen, V. Chen.</p>
                <p><italic>Supervision:</italic> Y. Chen, V. Chen.</p>
                <p content-type="COI-statement"><bold>Conflict of Interest Disclosures:</bold> Dr Stewart reported grants from Janssen and Takeda, nonfinancial support from GSK, and personal fees from Oxford University Press outside the submitted work. No other disclosures were reported.</p>
                <p content-type="funding-statement"><bold>Funding/Support:</bold> This study was supported in part by the Hospital and Social Welfare Organizations Administration Commission Grant (grant 11177). Dr Stewart is partially funded by (1) the National Institute for Health and Care Research (NIHR) Maudsley Biomedical Research Centre at the South London and Maudsley NHS Foundation Trust and King’s College London; (2) the NIHR Applied Research Collaboration South London (NIHR ARC South London) at King’s College Hospital NHS Foundation Trust; (iii) UKRI–Medical Research Council through the DATAMIND HDR UK Mental Health Data Hub (MRC reference MR/W014386); and (4) the UK Prevention Research Partnership (Violence, Health and Society; MR-VO49879/1), an initiative funded by UK Research and Innovation Councils, the Department of Health and Social Care (England) and the UK devolved administrations, and leading health research charities.</p>
                <p><bold>Role of the Funder/Sponsor:</bold> The funder had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.</p>
                <p content-type="data-sharing-statement"><bold>Data Sharing Statement:</bold> See <xref rid="note-ZOI230944-1-s" ref-type="supplementary-material">Supplement 2</xref>.</p>
              </author-notes>
              <pub-date pub-type="epub" iso-8601-date="2023-09-06T10:00">
                <day>6</day>
                <month>9</month>
                <year>2023</year>
              </pub-date>
              <pub-date pub-type="collection">
                <month>9</month>
                <year>2023</year>
              </pub-date>
              <pub-date pub-type="pmc-release">
                <day>6</day>
                <month>9</month>
                <year>2023</year>
              </pub-date>
              <!--PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>.-->
              <volume>6</volume>
              <issue>9</issue>
              <elocation-id>e2332579</elocation-id>
              <history>
                <date date-type="received">
                  <day>4</day>
                  <month>3</month>
                  <year>2023</year>
                </date>
                <date date-type="accepted">
                  <day>31</day>
                  <month>7</month>
                  <year>2023</year>
                </date>
              </history>
              <permissions>
                <copyright-statement>Copyright 2023 Huang KL et al. <italic>JAMA Network Open</italic>.</copyright-statement>
                <license>
                  <ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
                  <license-p>This is an open access article distributed under the terms of the CC-BY License.</license-p>
                </license>
              </permissions>
              <self-uri content-type="pdf-version" xlink:href="jamanetwopen-e2332579.pdf">jamanetwopen-e2332579.pdf</self-uri>
              <self-uri content-type="silverchair" xlink:href="https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2023.32579"/>
              <abstract abstract-type="teaser" specific-use="electronic">
                <p>This cohort study investigates the association between antidepressant use and mortality risk in patients with hepatocellular carcinoma.</p>
              </abstract>
              <abstract abstract-type="key-points">
                <title>Key Points</title>
                <sec id="ab-zoi230944-1">
                  <title>Question</title>
                  <p>Is the use of antidepressants associated with a lower risk of death in patients with hepatocellular carcinoma (HCC)?</p>
                </sec>
                <sec id="ab-zoi230944-2">
                  <title>Findings</title>
                  <p>In this population-based cohort study of 308 938 participants with HCC, the use of antidepressants after HCC diagnosis was associated with lower overall and cancer-specific mortality. The association was consistent across subgroups with different antidepressant classes and comorbidities.</p>
                </sec>
                <sec id="ab-zoi230944-3">
                  <title>Meaning</title>
                  <p>This study supports an inverse association between antidepressant use after HCC diagnosis and mortality risk in patients with HCC.</p>
                </sec>
              </abstract>
              <abstract>
                <sec id="ab-zoi230944-4">
                  <title>Importance</title>
                  <p>Liver cancer, primarily hepatocellular carcinoma (HCC), is the third leading cause of cancer deaths worldwide. Although some studies have proposed that antidepressants may have apoptotic effects on cancer, no study has examined the association between antidepressant use and HCC prognosis.</p>
                </sec>
                <sec id="ab-zoi230944-5">
                  <title>Objective</title>
                  <p>To investigate the association between antidepressant use and mortality risk in patients with HCC.</p>
                </sec>
                <sec id="ab-zoi230944-6">
                  <title>Design, Setting, and Participants</title>
                  <p>This population-based cohort study analyzed Taiwan’s National Health Insurance Research Database, which covers 99% of Taiwan’s population and includes comprehensive medical information. Patients with a new diagnosis of HCC between 1999 and 2017 were identified. Analysis took place in June 2023.</p>
                </sec>
                <sec id="ab-zoi230944-7">
                  <title>Main Outcomes and Measures</title>
                  <p>All patients with HCC were followed up until 2018 to measure overall and cancer-specific mortality. To examine whether the timing of antidepressant use influenced the association with mortality, antidepressant use was examined before and after HCC diagnosis. Cox proportional hazards regression was performed to estimate hazard ratios (HRs) and the 95% CIs for the association between antidepressant use and overall mortality and cancer-specific mortality.</p>
                </sec>
                <sec id="ab-zoi230944-8">
                  <title>Results</title>
                  <p>The study cohort comprised 308 938 participants, primarily consisting of older individuals (131 991 [42.7%] were aged ≥65 years) with a higher proportion of male individuals (202 589 [65.6%]). Antidepressant use before the diagnosis of HCC was not associated with lower risks of overall mortality (adjusted HR, 1.10; 95% CI, 1.08-1.12) and cancer-specific mortality (adjusted HR, 1.06; 95% CI, 0.96-1.17). However, antidepressant use after a diagnosis of HCC was associated with a lower risk of overall mortality (adjusted HR, 0.69; 95% CI, 0.68-0.70) and cancer-specific mortality (adjusted HR, 0.63; 95% CI, 0.59-0.68). The observed associations were consistent across subgroups with different antidepressant classes and comorbidities, including hepatitis B virus or hepatitis C virus infection, liver cirrhosis, and alcohol use disorders.</p>
                </sec>
                <sec id="ab-zoi230944-9">
                  <title>Conclusions and Relevance</title>
                  <p>Based on this nationwide cohort study, postdiagnosis antidepressant use may be associated with lower mortality in patients with HCC. Further randomized clinical trial evaluation should be considered.</p>
                </sec>
              </abstract>
            </article-meta>
          </front>
          <body>
            <sec id="H1-1-ZOI230944">
              <title>Introduction</title>
              <p>Liver cancer is the sixth most commonly diagnosed cancer and the third leading cancer-related cause of death worldwide, and among the different forms of primary liver cancers, hepatocellular carcinoma (HCC) is the most common, accounting for 75% to 90% of cases.<sup><xref rid="zoi230944r1" ref-type="bibr">1</xref></sup> Patients with early HCC can be treated with curative therapies including resection, transplant, and ablation, leading to an expected overall survival time of more than 6 years.<sup><xref rid="zoi230944r2" ref-type="bibr">2</xref></sup> However, the majority (&gt;70%) of patients with HCC have a diagnosis at advanced stages because the symptoms of early HCC are not easily detected. Surgical intervention is not suitable for those with advanced HCC,<sup><xref rid="zoi230944r3" ref-type="bibr">3</xref></sup> and the median survival time at this point is only 8 to 19 months.<sup><xref rid="zoi230944r2" ref-type="bibr">2</xref>,<xref rid="zoi230944r4" ref-type="bibr">4</xref></sup> There is therefore an urgent need for research into alternative anticancer therapies, and drug repurposing based on the potential anticancerous effects of existing nononcological drugs is attracting interest as an approach.</p>
              <p>Antidepressants are commonly used drugs that have potential anticancer effects.<sup><xref rid="zoi230944r5" ref-type="bibr">5</xref></sup> Preclinical and epidemiological studies examining the anticancer effects of antidepressants, including tricyclic antidepressants (TCAs), selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), and other atypical antidepressants, have increased. Early animal studies reported that SSRI use was associated with increased liver cancer,<sup><xref rid="zoi230944r6" ref-type="bibr">6</xref></sup> but other studies reported conflicting findings.<sup><xref rid="zoi230944r7" ref-type="bibr">7</xref></sup> Promising results for TCAs and SSRIs in HCC have been reported from in vitro and in vivo animal studies<sup><xref rid="zoi230944r8" ref-type="bibr">8</xref>,<xref rid="zoi230944r9" ref-type="bibr">9</xref>,<xref rid="zoi230944r10" ref-type="bibr">10</xref>,<xref rid="zoi230944r11" ref-type="bibr">11</xref>,<xref rid="zoi230944r12" ref-type="bibr">12</xref></sup> and epidemiological human studies.<sup><xref rid="zoi230944r13" ref-type="bibr">13</xref>,<xref rid="zoi230944r14" ref-type="bibr">14</xref></sup> Although these epidemiological studies have reported associations of antidepressants with lower risk of HCC, associations with HCC prognosis have not been evaluated.</p>
              <p>Therefore, we conducted a national cohort study to examine the association between antidepressants and HCC prognosis. We investigated overall and cancer-specific mortality as HCC prognosis indices. To examine whether the timing of antidepressant use influenced the association with HCC prognosis, we distinguished between antidepressant use before and after HCC diagnosis.</p>
            </sec>
            <sec id="H1-2-ZOI230944">
              <title>Methods</title>
              <sec id="H2-1-ZOI230944">
                <title>Study Design and Population</title>
                <p>Enrollment in Taiwan’s National Health Insurance program is mandatory for all residents; it is run by the Taiwanese government and covers 99% of Taiwan’s population. The National Health Insurance Research Database (NHIRD) is comprehensive and includes information on medical procedures, prescriptions, and diagnoses in outpatient, inpatient, and emergency care. Individual medical records included in the NHIRD are anonymized to protect patient privacy. Diseases in the NHIRD were diagnosed and recorded using the <italic>International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM)</italic> before 2015 and the <italic>International Statistical Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM)</italic> after 2015. Validation studies have demonstrated the validity of NHIRD diagnosis codes. The validity of cancer diagnosis recorded in the NHIRD has been tested by comparison with the Taiwan Cancer Registry and the positive predictive value was 93% for liver cancer diagnosis recorded in NHIRD.<sup><xref rid="zoi230944r15" ref-type="bibr">15</xref></sup> High concordance between claim records for medication use in the NHIRD and patient self-report has also been established.<sup><xref rid="zoi230944r16" ref-type="bibr">16</xref></sup> The study was approved by the Research Ethics Committee of the Chang Gung Medical Foundation. Written informed consent was not needed because this study used Taiwan’s NHIRD, which covers all residents, with research legitimacy affirmed by the Supreme Administrative Court in 2017. This study was conducted in accordance with the Strengthening the Reporting of Observational Studies in Epidemiology (<ext-link xlink:href="http://www.equator-network.org/reporting-guidelines/strobe/" ext-link-type="uri">STROBE</ext-link>) reporting guideline.</p>
              </sec>
              <sec id="H2-2-ZOI230944">
                <title>Cohort Selection</title>
                <p>A cohort of patients with a new HCC diagnosis was identified based on <italic>ICD-9-CM</italic> code 155.0 and <italic>ICD-10-CM</italic> codes C22.0, C22.2, C22.7, and C22.8 recorded in the NHIRD between January 1, 1999, and December 31, 2017. It has been reported that use of prevalent case may result in selection bias.<sup><xref rid="zoi230944r17" ref-type="bibr">17</xref></sup> To exclude prevalent cases of HCC that occurred before January 1, 1999, a 1-year exclusion assessment window was applied from January 1 to December 31, 1998. By excluding prevalent cases of HCC, we identified incident cases of HCC for analysis. The cohort entry date was the date of HCC diagnosis. The end of this study was December 31, 2018, to ensure a minimum 1-year follow-up window.</p>
              </sec>
              <sec id="H2-3-ZOI230944">
                <title>Main Exposure</title>
                <p>Antidepressant prescription records were obtained from the NHIRD based on the Anatomical Therapeutic Chemical (ATC) code N06A. Antidepressant use was indicated by the presence of 1 or more prescriptions for antidepressants. We divided antidepressants into 3 classes: (1) SSRIs (ATC code N06AB), (2) SNRIs (ATC codes N06AX16 and N06AX21), and (3) TCAs (ATC code AN06AA). Individuals in each antidepressant subgroup were not mutually exclusive. In addition to these 3 major classes of antidepressants, the users of remaining atypical antidepressants such as bupropion, mirtazapine, and trazodone were categorized as other antidepressants in <xref rid="zoi230944t1" ref-type="table">Table 1</xref> but were not counted in the subgroup analysis due to heterogeneity. To examine whether the timing of antidepressant use influenced the association between antidepressant use and mortality, we conducted separate analyses for antidepressant use before and after HCC diagnosis. In each comparison, the groups using antidepressants before and after the diagnosis of HCC were not mutually exclusive.</p>
                <table-wrap position="float" id="zoi230944t1">
                  <label>Table 1. </label>
                  <caption>
                    <title>Characteristics of Patients With HCC by Antidepressant Use Before or After Diagnosis</title>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <col width="22.04%" span="1"/>
                    <col width="18.99%" span="1"/>
                    <col width="21.02%" span="1"/>
                    <col width="18.99%" span="1"/>
                    <col width="18.96%" span="1"/>
                    <thead>
                      <tr>
                        <th rowspan="3" valign="top" align="left" scope="col" colspan="1">Characteristic</th>
                        <th colspan="4" valign="top" align="left" scope="colgroup" rowspan="1">No. (%)</th>
                      </tr>
                      <tr>
                        <th colspan="2" valign="top" align="left" scope="colgroup" rowspan="1">Antidepressant use in a year before HCC diagnosis</th>
                        <th colspan="2" valign="top" align="left" scope="colgroup" rowspan="1">Antidepressant use after HCC diagnosis</th>
                      </tr>
                      <tr>
                        <th valign="top" colspan="1" align="left" scope="colgroup" rowspan="1">Antidepressant use (n = 21 202)</th>
                        <th valign="top" align="left" scope="col" rowspan="1" colspan="1">Nonuse (n = 287 736)<xref rid="zoi230944t1n1" ref-type="table-fn"><sup>a</sup></xref></th>
                        <th valign="top" align="left" scope="col" rowspan="1" colspan="1">Antidepressant use (n = 66 211)</th>
                        <th valign="top" align="left" scope="col" rowspan="1" colspan="1">Nonuse (n = 235 083)<xref rid="zoi230944t1n2" ref-type="table-fn"><sup>b</sup></xref></th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td valign="top" align="left" scope="col" rowspan="1" colspan="1">Age at diagnosis, y</td>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> &lt;45</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">1828 (8.6)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">42 907 (14.9)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">9951 (15.0)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">34 332 (14.6)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> 45-54</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">3230 (15.2)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">54 563 (19.0)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">12 886 (19.5)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">43 904 (18.7)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> 55-64</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">4820 (22.7)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">69 599 (24.2)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">16 391 (24.8)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">56 462 (24.0)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> ≥65</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">11 324 (53.4)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">120 667 (41.9)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">26 983 (40.8)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">100 385 (42.7)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="col" rowspan="1" colspan="1">Sex</td>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Male</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">12 593 (59.4)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">189 996 (66.0)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">38 361 (57.9)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">159 427 (67.8)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Female</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">8609 (40.6)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">97 740 (34.0)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">27 850 (42.1)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">75 656 (32.2)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Low-income status</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">551 (2.6)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">3992 (1.4)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">1428 (2.2)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">3021 (1.3)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="col" rowspan="1" colspan="1">Comorbidity<xref rid="zoi230944t1n3" ref-type="table-fn"><sup>c</sup></xref></td>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Hepatitis B virus </td>
                        <td valign="top" align="left" rowspan="1" colspan="1">6990 (33.0)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">107 967 (37.5)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">23 044 (34.8)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">89 567 (38.1)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Hepatitis C virus </td>
                        <td valign="top" align="left" rowspan="1" colspan="1">5326 (25.1)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">51 350 (17.8)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">15 662 (23.7)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">39 525 (16.8)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Liver cirrhosis</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">12 016 (56.7)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">163 219 (56.7)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">32 872 (49.6)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">137 815 (58.6)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Alcohol use disorder</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">1614 (7.6)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">10 145 (3.5)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">3653 (5.5)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">7706 (3.3)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1">CCI score, median (IQR)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">10 (7-14)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">8 (6-12)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">9 (6-13)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">8 (6-12)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="col" rowspan="1" colspan="1">HCC treatment<xref rid="zoi230944t1n4" ref-type="table-fn"><sup>d</sup></xref></td>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Hepatic operation</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">NA</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">NA</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">13 207 (19.9)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">38 297 (16.3)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> RFA</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">NA</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">NA</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">9431 (14.2)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">25 738 (10.9)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> TAE/TACE</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">NA</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">NA</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">25 314 (38.2)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">90 213 (38.4)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Radiotherapy</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">NA</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">NA</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">22 306 (33.7)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">81 320 (34.6)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Chemotherapy</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">NA</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">NA</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">523 (0.8)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">11 053 (4.7)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Sorafenib</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">NA</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">NA</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">1300 (2.0)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">14 579 (6.2)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="col" rowspan="1" colspan="1">Antidepressant subclasses, No. (%)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> SSRI</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">5948 (28.1)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">NA</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">23 158 (35.0)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">NA</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> SNRI</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">1325 (6.2)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">NA</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">6993 (10.6)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">NA</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> TCA</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">9597 (45.3)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">NA</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">40 949 (61.8)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">NA</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Other antidepressants</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">5702 (26.9)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">NA</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">11 568 (17.5)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">NA</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot>
                    <p>Abbreviations: CCI, Charlson Comorbidity Index; HCC, hepatocellular carcinoma; NA, not applicable; RFA, radiofrequency ablation; SNRI, serotonin-norepinephrine reuptake inhibitor; SSRI, selective serotonin reuptake inhibitor; TACE, transcatheter arterial chemoembolization; TAE, transcatheter arterial embolization; TCA, tricyclic antidepressant.</p>
                    <fn id="zoi230944t1n1">
                      <label>
                        <sup>a</sup>
                      </label>
                      <p>Without an antidepressant prescription in the 1 year before the HCC diagnosis.</p>
                    </fn>
                    <fn id="zoi230944t1n2">
                      <label>
                        <sup>b</sup>
                      </label>
                      <p>Without an antidepressant prescription in the 1 year before and after the HCC diagnosis.</p>
                    </fn>
                    <fn id="zoi230944t1n3">
                      <label>
                        <sup>c</sup>
                      </label>
                      <p>Comorbidity before HCC diagnosis.</p>
                    </fn>
                    <fn id="zoi230944t1n4">
                      <label>
                        <sup>d</sup>
                      </label>
                      <p>Procedures and medication use recorded after HCC diagnosis.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
                <p>For comparisons of antidepressant use prior to diagnosis, antidepressant use was defined as having at least 1 antidepressant prescription in the 1-year exposure window prior to HCC diagnosis, regardless of prior antidepressant use. Nonuse was defined as individuals who had no prescriptions for antidepressants in the 1-year exposure window prior to HCC diagnosis.</p>
                <p>For comparisons of antidepressant use after diagnosis, those taking antidepressants were defined by at least 1 antidepressant prescription in the exposure assessment window after the date of first HCC diagnosis to death or the end of 2017. Antidepressant use was considered as a time-varying exposure to avoid potential immortal time bias.<sup><xref rid="zoi230944r18" ref-type="bibr">18</xref></sup> Specifically, for individuals taking antidepressants, the period between HCC diagnosis and the time of first antidepressant plus a 90-day induction period<sup><xref rid="zoi230944r19" ref-type="bibr">19</xref></sup> was classified as nonexposure time, and the period thereafter during follow-up was classified as exposure time. To examine the influence of induction period on the results, we performed sensitivity analysis using different induction period times (0 and 180 days). Nonusers were defined as individuals who had no prescriptions for antidepressants in the 1 year before or after HCC diagnosis to death or the end of 2017. For nonusers, their entire follow-up period was classified as nonexposure time.</p>
              </sec>
              <sec id="H2-4-ZOI230944">
                <title>Covariates</title>
                <p>Study covariates were included based on their relevance to antidepressant use and HCC prognosis and included demographic characteristics, comorbidities, and treatments for HCC.<sup><xref rid="zoi230944r20" ref-type="bibr">20</xref>,<xref rid="zoi230944r21" ref-type="bibr">21</xref></sup> Covariate assessment windows were the time before the HCC diagnosis for relevant comorbidities, at the date of HCC diagnosis for demographic characteristics, and the time after the HCC diagnosis for HCC treatments. Among these covariates, treatments for HCC were exclusive to analysis of antidepressant use after HCC diagnosis. HCC treatment variables are more likely to be mediators of prediagnostic analyses, so adjusting for such variables is unnecessary overadjustment.<sup><xref rid="zoi230944r22" ref-type="bibr">22</xref></sup></p>
                <p>Comorbidities including hepatitis B virus (HBV) infection, hepatitis C virus (HCV) infection, liver cirrhosis, alcohol use disorder, and other diseases were defined as being present if data on diagnostic codes corresponding to these comorbidities were assigned to the patient for at least 3 outpatient visits or at least 1 hospital admission before HCC diagnosis. We used the Charlson Comorbidity Index (CCI) to determine general health conditions and the overall burden of comorbidities.<sup><xref rid="zoi230944r20" ref-type="bibr">20</xref>,<xref rid="zoi230944r23" ref-type="bibr">23</xref></sup></p>
                <p>Treatments for HCC after HCC diagnosis were considered as covariates in the analysis of antidepressant use after HCC diagnosis.<sup><xref rid="zoi230944r20" ref-type="bibr">20</xref></sup> Data regarding HCC treatments, including hepatic operation (lobectomy, segmentectomy, hepatectomy, liver transplant), radiofrequency ablation, transcatheter arterial embolization, and transcatheter arterial chemoembolization, were retrieved from NHIRD inpatient and outpatient databased on <italic>ICD-9</italic> and <italic>ICD-10</italic> procedure codes. Data regarding sorafenib and chemotherapy for HCC, including fluorouracil, gemcitabine, docetaxel, irinotecan, doxorubicin, mitomycin, cisplatin, carboplatin, and oxaliplatin, were obtained from the NHIRD using ATC codes.</p>
              </sec>
              <sec id="H2-5-ZOI230944">
                <title>Study Outcomes</title>
                <p>Overall mortality and cancer-specific mortality were the primary outcomes in this study and were based on cause of death records in the NHIRD. Cancer-specific deaths were identified in the primary cause of death certification records based on <italic>ICD-9-CM</italic> code 155.0 and <italic>ICD-10-CM</italic> codes C22.0, C22.2, C22.7, and C22.8. The follow-up window for mortality was from the date of HCC diagnosis to the study end point (December 31, 2018).</p>
              </sec>
              <sec id="H2-6-ZOI230944">
                <title>Statistical Analysis</title>
                <p>All data analysis was performed using SAS statistical software version 9.4 (SAS Institute) and was conducted on June 5, 2023. A 2-sided hypothesis test was used with a significance level set at .05.</p>
                <p>We reported the distribution of demographics, comorbidities, and hepatic treatment and median and IQR of CCI score between the antidepressant use and nonuse groups. Cox proportional hazards regression was performed to estimate hazard ratios (HRs) with 95% CIs for associations between antidepressant use before and after HCC diagnosis and the rates of overall and cancer-specific mortality, with adjustments for demographic factors, comorbidities, and hepatic treatment. Both crude and adjusted HRs were reported to provide a comprehensive understanding of the associations. 95% CIs that did not include 1 indicate statistical significance. Dose-response analyses were conducted to examine whether the duration of antidepressant use had a differential association with overall and cancer-specific mortality rates. We categorized the duration of antidepressant use 2 groups: short-term users (1 to 90 days) and long-term users (&gt;90 days) because the practice of providing refillable prescriptions for up to 3 months to patients with chronic conditions in Taiwan; other studies also used such duration lengths.<sup><xref rid="zoi230944r24" ref-type="bibr">24</xref>,<xref rid="zoi230944r25" ref-type="bibr">25</xref>,<xref rid="zoi230944r26" ref-type="bibr">26</xref></sup> To investigate the association of antidepressant therapy with the prognosis of HCC in different etiological subgroups, we conducted a subgroup analysis focusing on specific subgroups, including HBV infection, HCV infection, liver cirrhosis, and alcohol use disorder. To determine whether there is an additional association of antidepressant use in conjunction with chemotherapy or sorafenib, we conducted moderation analysis to examine the association of combined use of sorafenib or chemotherapy with antidepressant compared with mortality.</p>
                <p>To address the type I error that may result from multiple comparisons and to provide more reliable results, we adjusted the <italic>P</italic> values for false discovery rate in both the main analysis and the subgroup analysis.<sup><xref rid="zoi230944r27" ref-type="bibr">27</xref></sup></p>
              </sec>
            </sec>
            <sec id="H1-3-ZOI230944">
              <title>Results</title>
              <sec id="H2-7-ZOI230944">
                <title>Study Cohort</title>
                <p>A total of 308 938 patients with HCC between 1999 and 2017 were identified from the NHIRD, after excluding 9173 patients with HCC diagnosis before January 1, 1999. For the comparison of antidepressant use before HCC diagnosis, we identified 21 202 patients with antidepressant exposure within 1 year before HCC diagnosis, and we had a nonuser group of 287 736 individuals. For the comparison of antidepressant use after HCC diagnosis, we identified 66 211 patients with antidepressant prescriptions after HCC diagnosis, and there were 235 083 nonusers in the comparison group (<xref rid="zoi230944f1" ref-type="fig">Figure 1</xref> and <xref rid="zoi230944f2" ref-type="fig">Figure 2</xref>). The distributions of baseline characteristics for each group in the 2 comparisons are shown in <xref rid="zoi230944t1" ref-type="table">Table 1</xref>. Across all groups, the majority of HCC diagnoses occurred in older individuals, with individuals 65 years and older ranging from 26 983 (40.8%) and 11 324 (53.4%) in participants based on antidepressant use before and after diagnosis, respectively. Male individuals predominated in terms of sex distribution, accounting for 38 361 participants (57.9%) and 159 427 participants (42.7%) based on antidepressant use before and after diagnosis, respectively. Individuals taking antidepressants, both before or after HCC diagnosis, were more likely to be female or have low-income status, HCV, alcohol use disorders, or higher CCI scores than nonusers. The antidepressant use group after HCC diagnosis had higher rates of undergoing hepatic operation and radiofrequency ablation and lower rates of receiving chemotherapy and sorafenib therapy than the nonuse group.</p>
                <fig position="float" id="zoi230944f1" fig-type="figure">
                  <label>Figure 1. </label>
                  <caption>
                    <title>Flowchart of Study Participants Based on Antidepressant Use Before Diagnosis</title>
                    <p>HCC indicates hepatocellular carcinoma.</p>
                  </caption>
                  <graphic xlink:href="jamanetwopen-e2332579-g001" position="float"/>
                </fig>
                <fig position="float" id="zoi230944f2" fig-type="figure">
                  <label>Figure 2. </label>
                  <caption>
                    <title>Flowchart of Study Participants Based on Antidepressant Use After Diagnosis</title>
                    <p>HCC indicates hepatocellular carcinoma.</p>
                  </caption>
                  <graphic xlink:href="jamanetwopen-e2332579-g002" position="float"/>
                </fig>
              </sec>
              <sec id="H2-8-ZOI230944">
                <title>Association Between Mortality and Antidepressant Use Before HCC Diagnosis</title>
                <p>The crude overall mortality rates were 15.68 per 100 person-years in the antidepressant use group and 12.14 per 100 person-years in the nonuse group (<xref rid="zoi230944t2" ref-type="table">Table 2</xref>). In patients with HCC, use of any type of antidepressant within 1 year before diagnosis was not associated with a lower overall mortality but instead with a slightly higher risk after adjustment for covariates (adjusted HR, 1.10; 95% CI, 1.08-1.12). Additional analyses were conducted to examine the specific association of antidepressant types, including SSRI, SNRI, and TCA, with overall mortality. The results revealed no association with reduction in overall mortality, with adjusted HRs ranging from 1.03 (95% CI, 1.00-1.05) to 1.16 (95% CI, 1.07-1.25) when compared with nonuse.</p>
                <table-wrap position="float" id="zoi230944t2">
                  <?xpp landscape?>
                  <label>Table 2. </label>
                  <caption>
                    <title>Association Between Antidepressant Use and Mortality in Patients With HCC </title>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <col width="9.88%" span="1"/>
                    <col width="5.88%" span="1"/>
                    <col width="5.97%" span="1"/>
                    <col width="7.15%" span="1"/>
                    <col width="7.7%" span="1"/>
                    <col width="4.84%" span="1"/>
                    <col width="8.04%" span="1"/>
                    <col width="5.17%" span="1"/>
                    <col width="6.32%" span="1"/>
                    <col width="6.34%" span="1"/>
                    <col width="7.45%" span="1"/>
                    <col width="8.04%" span="1"/>
                    <col width="4.59%" span="1"/>
                    <col width="8.04%" span="1"/>
                    <col width="4.59%" span="1"/>
                    <thead>
                      <tr>
                        <th rowspan="2" valign="top" align="left" scope="col" colspan="1">Factor</th>
                        <th colspan="7" valign="top" align="left" scope="colgroup" rowspan="1">Antidepressant use 1 y before diagnosis<xref rid="zoi230944t2n1" ref-type="table-fn"><sup>a</sup></xref></th>
                        <th colspan="7" valign="top" align="left" scope="colgroup" rowspan="1">Antidepressant use after diagnosis<xref rid="zoi230944t2n2" ref-type="table-fn"><sup>b</sup></xref></th>
                      </tr>
                      <tr>
                        <th valign="top" colspan="1" align="left" scope="colgroup" rowspan="1">Deaths, No.</th>
                        <th valign="top" align="left" scope="col" rowspan="1" colspan="1">Person-years</th>
                        <th valign="top" align="left" scope="col" rowspan="1" colspan="1">Mortality rate (per 100 person-years)</th>
                        <th valign="top" align="left" scope="col" rowspan="1" colspan="1">Crude HR (95% CI)</th>
                        <th valign="top" align="left" scope="col" rowspan="1" colspan="1"><italic>P</italic> value<xref rid="zoi230944t2n3" ref-type="table-fn"><sup>c</sup></xref></th>
                        <th valign="top" align="left" scope="col" rowspan="1" colspan="1">Adjusted HR (95% CI)</th>
                        <th valign="top" align="left" scope="col" rowspan="1" colspan="1"><italic>P</italic> value<xref rid="zoi230944t2n3" ref-type="table-fn"><sup>c</sup></xref></th>
                        <th valign="top" align="left" scope="col" rowspan="1" colspan="1">Deaths, No.</th>
                        <th valign="top" align="left" scope="col" rowspan="1" colspan="1">Person-years</th>
                        <th valign="top" align="left" scope="col" rowspan="1" colspan="1">Mortality rate (per 100 person-years)</th>
                        <th valign="top" align="left" scope="col" rowspan="1" colspan="1">Crude HR (95% CI)</th>
                        <th valign="top" align="left" scope="col" rowspan="1" colspan="1"><italic>P</italic> value<xref rid="zoi230944t2n3" ref-type="table-fn"><sup>c</sup></xref></th>
                        <th valign="top" align="left" scope="col" rowspan="1" colspan="1">Adjusted HR (95% CI)</th>
                        <th valign="top" align="left" scope="col" rowspan="1" colspan="1"><italic>P</italic> value<xref rid="zoi230944t2n3" ref-type="table-fn"><sup>c</sup></xref></th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td colspan="15" valign="top" align="left" scope="col" rowspan="1">
                          <bold>Overall mortality</bold>
                        </td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Antidepressant use</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">13 616</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">86 864</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">15.68</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">1.09 (1.07-1.11)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">&lt;.001</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">1.10 (1.08-1.12)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">&lt;.001</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">31 908</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">318 122</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">10.03</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">0.73 (0.72-0.74)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">&lt;.001</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">0.69 (0.68-0.70)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">&lt;.001</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="col" rowspan="1" colspan="1"> Cumulative duration, d</td>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> 1-90</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">10 140</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">64 108</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">15.82</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">1.39 (1.36-1.42)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">&lt;.001</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">1.11 (1.09-1.14)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">&lt;.001</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">18 817</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">177 803</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">10.58</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">0.72 (0.70-0.73)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">&lt;.001</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">0.69 (0.68-0.70)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">&lt;.001</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> &gt;90</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">3476</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">22 756</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">15.28</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">1.36 (1.32-1.41)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">&lt;.001</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">1.07 (1.04-1.11)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">&lt;.001</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">13 091</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">140 319</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">9.33</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">0.75 (0.73-0.76)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">&lt;.001</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">0.68 (0.66-0.69)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">&lt;.001</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="col" rowspan="1" colspan="1"> Subclasses</td>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> SSRI</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">3475</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">25 496</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">13.63</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">0.98 (0.95-1.02)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">.20</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">1.13 (1.09-1.17)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">&lt;.001</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">9419</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">209 035</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">4.51</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">0.59 (0.58-0.60)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">&lt;.001</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">0.62 (0.61-0.64)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">&lt;.001</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> SNRI</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">708</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">5205</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">13.60</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">1.04 (0.97-1.12)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">.27</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">1.16 (1.07-1.25)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">&lt;.001</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">2422</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">66 961</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">3.62</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">0.54 (0.52-0.57)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">&lt;.001</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">0.60 (0.57-0.62)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">&lt;.001</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> TCA</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">8045</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">53 451</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">15.05</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">1.02 (1.00-1.05)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">.050</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">1.03 (1.00-1.05)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">.050</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">20 687</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">413 524</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">5.00</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">0.63 (0.62-0.64)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">&lt;.001</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">0.60 (0.59-0.60)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">&lt;.001</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Nonuse</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">174 415</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">1 437 045</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">12.14</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">1 [Reference]</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">NA</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">1 [Reference]</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">NA</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">150 026</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">970 848</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">15.45</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">1 [Reference]</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">NA</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">1 [Reference]</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">NA</td>
                      </tr>
                      <tr>
                        <td colspan="15" valign="top" align="left" scope="col" rowspan="1">
                          <bold>Cancer mortality</bold>
                        </td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Antidepressant use</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">455</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">86 864</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">0.52</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">1.00 (0.90-1.10)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">&gt;.99</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">1.06 (0.96-1.17)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">.25</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">1022</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">318 122</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">0.32</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">0.57 (0.53-0.62)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">&lt;.001</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">0.63 (0.59-0.68)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">&lt;.001</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="col" rowspan="1" colspan="1"> Cumulative duration, d</td>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> 1-90</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">338</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">64 108</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">0.53</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">1.27 (1.14-1.42)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">&lt;.001</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">1.08 (0.96-1.20)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">.20</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">618</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">177 803</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">0.35</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">0.59 (0.53-0.64)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">&lt;.001</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">0.65 (0.59-0.71)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">&lt;.001</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> &gt;90</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">117</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">22 756</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">0.51</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">1.24 (1.03-1.48)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">.02</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">1.01 (0.84-1.22)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">.92</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">404</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">140 319</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">0.29</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">0.56 (0.50-0.62)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">&lt;.001</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">0.61 (0.54-0.67)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">&lt;.001</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="col" rowspan="1" colspan="1"> Subclasses</td>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> SSRI</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">116</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">25 496</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">0.45</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">0.98 (0.95-1.02)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">.20</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">1.13 (1.09-1.17)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">&lt;.001</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">286</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">209 035</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">0.14</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">0.42 (0.37-0.48)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">&lt;.001</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">0.53 (0.47-0.61)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">&lt;.001</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> SNRI</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">25</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">5205</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">0.48</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">0.92 (0.62-1.36)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">.68</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">0.99 (0.67-1.47)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">.96</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">80</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">66 961</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">0.12</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">0.42 (0.34-0.54)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">&lt;.001</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">0.54 (0.42-0.68)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">&lt;.001</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> TCA</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">274</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">53 451</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">0.51</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">0.98 (0.87-1.10)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">.74</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">1.05 (0.93-1.19)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">.43</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">622</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">413 524</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">0.15</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">0.47 (0.43-0.52)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">&lt;.001</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">0.54 (0.49-0.59)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">&lt;.001</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Nonuse</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">6041</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">1 437 045</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">0.42</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">1 [Reference]</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">NA</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">1 [Reference]</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">NA</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">5286</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">970 848</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">0.54</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">1 [Reference]</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">NA</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">1 [Reference]</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">NA</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot>
                    <p>Abbreviations: HCC, hepatocellular carcinoma; HR, hazard ratio; SSRI, selective serotonin reuptake inhibitor; SNRI, serotonin-norepinephrine reuptake inhibitor; TCA, tricyclic antidepressant.</p>
                    <fn id="zoi230944t2n1">
                      <label>
                        <sup>a</sup>
                      </label>
                      <p>Adjusted for age, sex, low income, prediagnostic comorbidities (hepatitis B virus, hepatitis C virus, liver cirrhosis, alcohol use disorder), and Charlson Comorbidity Index score. Nonuse was defined as patients with HCC without an antidepressant prescription in the 1 year before the HCC diagnosis.</p>
                    </fn>
                    <fn id="zoi230944t2n2">
                      <label>
                        <sup>b</sup>
                      </label>
                      <p>Adjusted for age, sex, low income, prediagnostic comorbidities (hepatitis B virus, hepatitis C virus, liver cirrhosis, alcohol use disorder), Charlson Comorbidity Index score, and HCC treatment (operation, radiofrequency ablation, transcatheter arterial embolization/transcatheter arterial chemoembolization, radiotherapy, chemotherapy, sorafenib). Nonuse was defined as patients with HCC without an antidepressant prescription in the 1 year before and after the HCC diagnosis.</p>
                    </fn>
                    <fn id="zoi230944t2n3">
                      <label>
                        <sup>c</sup>
                      </label>
                      <p>False discovery rate–adjusted <italic>P</italic> value. The total numbers of multiple tests adjusted in the false discovery rate method is 11 for crude and adjusted HRs.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
                <p>A similar analysis was conducted for cancer-specific mortality. The crude cancer-specific mortality rate was 0.52 per 100 person-years in the antidepressant use group and 0.42 per 100 person-years in the nonuse group. We observed that antidepressant use before HCC diagnosis did not have a significant association with lower cancer-specific mortality (adjusted HR, 1.06; 95% CI, 0.96-1.17). When examining specific subgroups of antidepressants, none of them showed an association with the lower cancer-specific mortality, with adjusted HRs ranging from 0.99 (95% CI, 0.67-1.47) to 1.13 (95% CI, 1.09-1.17) when compared with nonuse.</p>
                <p>When examining the duration of antidepressant use in the 1-year exposure window prior to HCC diagnosis, both short-term (≤90 days) and long-term (&gt;90 days) antidepressant use displayed similar results regarding overall mortality (adjusted HR, 1.11; 95% CI, 1.09-1.14 and 1.07; 95% CI, 1.04-1.11, respectively) and cancer-specific mortality (adjusted HR, 1.08; 95% CI, 0.96-1.20 and 1.01; 95% CI, 0.84-1.22, respectively).</p>
              </sec>
              <sec id="H2-9-ZOI230944">
                <title>Association Between Mortality and Antidepressant Use After HCC Diagnosis</title>
                <p>The crude overall mortality rate was 10.03 per 100 person-years in the antidepressant use group after HCC diagnosis, lower than 15.45 per 100 person-years in the nonuse group. The crude overall mortality rate for antidepressant subgroups was even lower, ranging from 3.62 to 5.00 per 100 person-years. After adjustment for confounders, use of any antidepressant after diagnosis was associated with lower overall mortality (adjusted HR, 0.69; 95% CI, 0.68-0.70). When examining specific subgroups of antidepressants, the lower overall mortality were associated with postdiagnosis use of SSRI (adjusted HR, 0.62; 95% CI, 0.61-0.64), SNRI (adjusted HR, 0.60; 95% CI, 0.57-0.62), or TCA (adjusted HR, 0.60; 95% CI, 0.59-0.60).</p>
                <p>The crude cancer-specific mortality rates were 0.32 per 100 person-years in the combined antidepressant group, 0.12 to 0.15 per 100 person-years in different antidepressant subgroups, and 0.54 per 100 person-years in nonusers. Postdiagnosis antidepressant use was associated with a lower cancer-specific mortality (adjusted HR, 0.63; 95% CI, 0.59-0.68). The antidepressant subgroups, including SSRI (adjusted HR, 0.53; 95% CI, 0.47-0.61), SNRI (adjusted HR, 0.54; 95% CI, 0.42-0.68), and TCA (adjusted HR, 0.54; 95% CI, 0.49-0.59), demonstrated an inverse association with cancer-specific mortality.</p>
                <p>There was no apparent difference observed between short-term (≤90 days) and long-term (&gt;90 days) antidepressant use in terms of overall mortality (adjusted HRs, 0.69 [95% CI, 0.68-0.70] and 0.68 [95% CI, 0.66-0.69], respectively) and cancer-specific mortality (adjusted HRs, 0.65 [95% CI, 0.59-0.71] and 0.61 [95% CI, 0.54-0.67], respectively). The statistical significance inferred using the false discovery rate for multiple comparisons remained the same as it did with the 95% CIs.</p>
                <p>To examine the possible influence of the length of the induction period, we used different induction periods (0 days and 180 days) to examine the association of postdiagnosis antidepressant use, including the use of different antidepressant types, with overall and cancer-specific mortality. The results were similar to those for a 90-day induction period (eTable 1 in <xref rid="note-ZOI230944-1-s" ref-type="supplementary-material">Supplement 1</xref>).</p>
              </sec>
              <sec id="H2-10-ZOI230944">
                <title>Association Between Mortality and Antidepressant Use After HCC Diagnosis With Different Comorbidities</title>
                <p>A subgroup analysis was conducted to examine the use of antidepressants after diagnosis in different comorbidity subgroups. Analyses showed significant inverse associations between postdiagnosis antidepressant use and both overall and cancer-specific mortality in patients with HCC with HBV infection (adjusted HRs, 0.76 [95% CI, 0.75-0.78] and 0.67 [95% CI, 0.60-0.75], respectively), HCV infection (adjusted HRs, 0.92 [95% CI, 0.89-0.94] and 0.86 [95% CI, 0.76-0.98], respectively), liver cirrhosis (adjusted HRs, 0.76 [95% CI, 0.75-0.77] and 0.71 [95% CI, 0.65-0.77], respectively), and alcohol use disorder (adjusted HRs, 0.76 [95% CI, 0.72-0.80] and 0.72 [95% CI, 0.53-0.98], respectively) compared with nonuse (<xref rid="zoi230944t3" ref-type="table">Table 3</xref>). All the adjusted <italic>P</italic> values using the false discovery rate remained statistical significance (&lt;.05).</p>
                <table-wrap position="float" id="zoi230944t3">
                  <label>Table 3. </label>
                  <caption>
                    <title>Association Between Antidepressant Use and Mortality in Different Etiological Subgroups of Patients With HCC </title>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <col width="23.82%" span="1"/>
                    <col width="24.21%" span="1"/>
                    <col width="12.17%" span="1"/>
                    <col width="27.46%" span="1"/>
                    <col width="12.34%" span="1"/>
                    <thead>
                      <tr>
                        <th rowspan="2" valign="top" align="left" scope="col" colspan="1">Subgroup</th>
                        <th colspan="4" valign="top" align="left" scope="colgroup" rowspan="1">Antidepressant use after diagnosis</th>
                      </tr>
                      <tr>
                        <th valign="top" colspan="1" align="left" scope="colgroup" rowspan="1">Crude HR (95% CI)</th>
                        <th valign="top" align="left" scope="col" rowspan="1" colspan="1"><italic>P</italic> value<xref rid="zoi230944t3n1" ref-type="table-fn"><sup>a</sup></xref></th>
                        <th valign="top" align="left" scope="col" rowspan="1" colspan="1">Adjusted HR (95% CI)</th>
                        <th valign="top" align="left" scope="col" rowspan="1" colspan="1"><italic>P</italic> value<xref rid="zoi230944t3n2" ref-type="table-fn"><sup>b</sup></xref></th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td colspan="5" valign="top" align="left" scope="col" rowspan="1">
                          <bold>HBV</bold>
                        </td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Overall mortality</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">0.78 (0.77-0.80)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">&lt;.001</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">0.76 (0.75-0.78)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">&lt;.001</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Cancer mortality</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">0.63 (0.57-0.70)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">&lt;.001</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">0.67 (0.60-0.75)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">&lt;.001</td>
                      </tr>
                      <tr>
                        <td colspan="5" valign="top" align="left" scope="col" rowspan="1">
                          <bold>HCV</bold>
                        </td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Overall mortality</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">0.87 (0.85-0.90)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">&lt;.001</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">0.92 (0.89-0.94)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">&lt;.001</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Cancer mortality</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">0.77 (0.68-0.88)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">&lt;.001</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">0.86 (0.76-0.98)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">.02</td>
                      </tr>
                      <tr>
                        <td colspan="5" valign="top" align="left" scope="col" rowspan="1">
                          <bold>Liver cirrhosis</bold>
                        </td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Overall mortality</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">0.76 (0.75-0.77)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">&lt;.001</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">0.76 (0.75-0.77)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">&lt;.001</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Cancer mortality</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">0.65 (0.60-0.70)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">&lt;.001</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">0.71 (0.65-0.77)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">&lt;.001</td>
                      </tr>
                      <tr>
                        <td colspan="5" valign="top" align="left" scope="col" rowspan="1">
                          <bold>Alcohol use disorder</bold>
                        </td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Overall mortality</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">0.65 (0.62-0.69)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">&lt;.001</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">0.76 (0.72-0.80)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">&lt;.001</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Cancer mortality</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">0.52 (0.38-0.70)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">&lt;.001</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">0.72 (0.53-0.98)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">.04</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot>
                    <p>Abbreviations: HBV, hepatitis B virus; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; HR, hazard ratio.</p>
                    <fn id="zoi230944t3n1">
                      <label>
                        <sup>a</sup>
                      </label>
                      <p>Adjusted for age, sex, low income, prediagnostic comorbidities (HBV, HCV, liver cirrhosis, alcohol use disorder), Charlson Comorbidity Index score, and HCC treatment (operation, radiofrequency ablation, transcatheter arterial embolization/transcatheter arterial chemoembolization, radiotherapy, chemotherapy, sorafenib). Nonuse was defined as patients with HCC without an antidepressant prescription in the 1 year before and after the HCC diagnosis.</p>
                    </fn>
                    <fn id="zoi230944t3n2">
                      <label>
                        <sup>b</sup>
                      </label>
                      <p>False discovery rate–adjusted <italic>P</italic> value. The total numbers of multiple tests adjusted in the false discovery rate method is 8 for crude and adjusted HRs.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
              </sec>
              <sec id="H2-11-ZOI230944">
                <title>Association Between Mortality and Antidepressant Use After HCC Diagnosis With Chemotherapy or Sorafenib</title>
                <p>To investigate the potential effect of combination therapies, we examined the interaction between postdiagnosis antidepressant use and HCC treatments such as chemotherapy and sorafenib. None of the interaction tests between antidepressant and chemotherapy or antidepressant and sorafenib revealed additional beneficial associations with overall mortality or cancer-specific mortality. This finding was consistent across different antidepressant subgroups (eTable 2 in <xref rid="note-ZOI230944-1-s" ref-type="supplementary-material">Supplement 1</xref>).</p>
              </sec>
            </sec>
            <sec id="H1-4-ZOI230944">
              <title>Discussion</title>
              <p>This is the first national cohort study on the association between antidepressant use and mortality risk in patients with HCC. Our results demonstrate that the use of antidepressants after HCC diagnosis, including SSRI, SNRI, and TCA, was associated with decreased both overall and cancer-specific mortality in a large, representative cohort. Notably, we observed a consistent inverse association between postdiagnosis antidepressant use and mortality risk across various comorbidity subgroups, encompassing HBV infection, HCV infection, liver cirrhosis, and alcohol use disorder. In contrast, no association was observed between the use of antidepressants before HCC diagnosis and reduced cancer-specific mortality or all-cause mortality.</p>
              <p>Our study conducted 2 comparisons; examining the associations of antidepressant use before and after HCC diagnosis with mortality. The results showed inconsistent findings. Antidepressant use before HCC diagnosis was not associated with lower mortality risk, indicating that the antidepressant use prior to HCC diagnosis may not have an association with the severity of HCC and its subsequent prognosis. However, the use of antidepressants after HCC diagnosis was inversely associated with both overall and cancer-specific mortality. This suggests that antidepressant use might be involved in the prognosis of cancer, not before its induction. A similar finding was also observed that statin use after HCC diagnosis associated with lower HCC mortality but not in statin use before HCC diagnosis.<sup><xref rid="zoi230944r20" ref-type="bibr">20</xref></sup> Further studies are warranted to examine potential mechanisms of antidepressants use on HCC mortality.</p>
              <p>Considering the inverse association between overall mortality and antidepressant use after HCC diagnosis, several noncancer causes of death, such as unintentional injury, self-inflicted injury, and suicide, have been reported in patients with cancer, which may be reduced by antidepressant use. For example, risks of motor vehicle crashes<sup><xref rid="zoi230944r28" ref-type="bibr">28</xref></sup> and suicide attempts have been reported to decrease following the initiation of antidepressant treatment. Furthermore, depression has been commonly observed in patients with HCC and has been associated with a lower quality of life, lower adherence to anticancer treatment, prolonged hospitalization, and higher mortality.<sup><xref rid="zoi230944r29" ref-type="bibr">29</xref></sup> Adherence to antidepressant treatment has been shown to have a positive impact on mortality in patients with depression and cancer.<sup><xref rid="zoi230944r30" ref-type="bibr">30</xref></sup> It is possible that the prescription of antidepressants may act as a mediator, indirectly influencing the overall mortality risk in patients with HCC by mitigating the negative health effects of depression.</p>
              <p>In addition to observing lower risk of overall mortality, we observed that antidepressant use after HCC diagnosis was inversely associated with cancer-specific mortality. This association remained consistent when specifically analyzing different antidepressants including SSRIs, SNRIs, and TCAs. This might be explained by previously reported apoptotic effects of serotonergic antidepressants on cancer through the regulation of growth stimulatory 5-HT activity connected to biochemical pathways involving mitogen-activated protein kinase, mitochondrial membrane potential, extracellular signal-regulated kinases, protein kinase B, and nuclear transcription factor-κB.<sup><xref rid="zoi230944r31" ref-type="bibr">31</xref></sup> The apoptotic activity of TCAs and SSRIs has been observed in different tumor cell lines including HCC.<sup><xref rid="zoi230944r8" ref-type="bibr">8</xref>,<xref rid="zoi230944r10" ref-type="bibr">10</xref>,<xref rid="zoi230944r11" ref-type="bibr">11</xref>,<xref rid="zoi230944r32" ref-type="bibr">32</xref>,<xref rid="zoi230944r33" ref-type="bibr">33</xref></sup> In addition, some SSRIs (fluoxetine and sertraline) have been reported to be effective chemosensitizers that increase the cytotoxicity of anticancer drugs and suppress the growth of HCC cells.<sup><xref rid="zoi230944r32" ref-type="bibr">32</xref>,<xref rid="zoi230944r34" ref-type="bibr">34</xref></sup> However, our results did not reveal additional beneficial associations when examining the interaction between postdiagnosis antidepressant use and HCC treatments, including chemotherapy and sorafenib. The lack of synergistic interaction may be attributed to the different mechanisms of action between antidepressants and chemotherapy or sorafenib. Further research is warranted to explore the potential biological mechanisms underlying the inverse association between antidepressants and HCC mortality.</p>
              <p>Despite biological plausibility, studies have presented mixed results for associations of antidepressants with mortality in patients with cancer. Some studies have reported that antidepressant use in patients with depression and cancer has a beneficial effect on premature mortality,<sup><xref rid="zoi230944r30" ref-type="bibr">30</xref></sup> and antidepressant use was found to be associated with reduced mortality in lung cancer specifically.<sup><xref rid="zoi230944r35" ref-type="bibr">35</xref></sup> However, other researchers have reported contradictory findings, for example, that use of antidepressants in patients with melanoma, breast, prostate, lung, colorectal, and other cancers is associated with increased mortality.<sup><xref rid="zoi230944r21" ref-type="bibr">21</xref>,<xref rid="zoi230944r36" ref-type="bibr">36</xref></sup></p>
              <sec id="H2-12-ZOI230944">
                <title>Strengths and Limitations</title>
                <p>This study has several strengths. By using a nationally registered data set with a 99% coverage of the Taiwanese population, this large-scale cohort study has national representativeness and low potential for selection bias. Furthermore, we adjusted for a range of potential confounders and took into consideration the potential induction periods of antidepressants, the timing of antidepressant use (before and after HCC diagnosis), and types of mortality (overall and cancer specific). In our analysis of antidepressant use after HCC diagnosis, we used time-varying exposure to minimize immortal time bias. Therefore, this study yielded robust results on the association between mortality and postdiagnosis antidepressant use in patients with HCC.</p>
                <p>Several limitations may affect the results and interpretations of this study. First, information on some potential confounders was not available in the NHIRD, including adherence to antidepressant use, smoking status, body mass index, nutritional status, other health-related factors, and laboratory test results, and we thus could not include and adjust for them in our statistical models. Second, our study may have misclassification bias because some participants may not have adhered to antidepressant medication. However, such misclassification usually results in an underestimation of the effect of interest<sup><xref rid="zoi230944r37" ref-type="bibr">37</xref></sup>; therefore, the true association may be more pronounced. Third, the low cancer-specific mortality in our study could be attributed to our definition based on the primary cause of death certificate records, where complications of HCC (such as liver cirrhosis or infectious complications) may appear as primary causes of death, leading to an underestimation of cancer-specific mortality. Fourth, this study used Taiwanese population data, and the results might not be generalizable to other countries. Finally, it is important to acknowledge that the current evidence supporting the use of antidepressants in HCC is limited, and there are no HCC management consensus guidelines recommending their use.<sup><xref rid="zoi230944r38" ref-type="bibr">38</xref>,<xref rid="zoi230944r39" ref-type="bibr">39</xref></sup> Given that antidepressant use in our study was not specifically targeted at HCC treatment and the study design was retrospective and observational, caution is warranted when interpreting the observed associations.</p>
              </sec>
            </sec>
            <sec id="H1-5-ZOI230944">
              <title>Conclusions</title>
              <p>In this large population-based HCC cohort study, antidepressant use after HCC diagnosis was associated with lower overall and cancer-specific mortality among patients with HCC. Our study provides promising empirical results indicating that antidepressants may have utility as anticancer therapeutics in patients with HCC. However, our findings should be interpreted cautiously because the associations found in this observational study may not indicate causality and may be affected by residual confounding or biases. Definitive evidence would require evaluation in randomized clinical trials.</p>
            </sec>
          </body>
          <back>
            <ref-list id="REF-ZOI230944">
              <title>References</title>
              <ref id="zoi230944r1">
                <label>1</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Sung</surname><given-names>H</given-names></string-name>, <string-name><surname>Ferlay</surname><given-names>J</given-names></string-name>, <string-name><surname>Siegel</surname><given-names>RL</given-names></string-name>, <etal/></person-group>. <article-title>Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries</article-title>. <source>CA Cancer J Clin</source>. <year>2021</year>;<volume>71</volume>(<issue>3</issue>):<fpage>209</fpage>-<lpage>249</lpage>. doi:<pub-id pub-id-type="doi">10.3322/caac.21660</pub-id><?supplied-pmid 33538338?><pub-id pub-id-type="pmid">33538338</pub-id></mixed-citation>
              </ref>
              <ref id="zoi230944r2">
                <label>2</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Llovet</surname><given-names>JM</given-names></string-name>, <string-name><surname>Kelley</surname><given-names>RK</given-names></string-name>, <string-name><surname>Villanueva</surname><given-names>A</given-names></string-name>, <etal/></person-group>. <article-title>Hepatocellular carcinoma</article-title>. <source>Nat Rev Dis Primers</source>. <year>2021</year>;<volume>7</volume>(<issue>1</issue>):<fpage>6</fpage>. doi:<pub-id pub-id-type="doi">10.1038/s41572-020-00240-3</pub-id><?supplied-pmid 33479224?><pub-id pub-id-type="pmid">33479224</pub-id></mixed-citation>
              </ref>
              <ref id="zoi230944r3">
                <label>3</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Forner</surname><given-names>A</given-names></string-name>, <string-name><surname>Reig</surname><given-names>ME</given-names></string-name>, <string-name><surname>de Lope</surname><given-names>CR</given-names></string-name>, <string-name><surname>Bruix</surname><given-names>J</given-names></string-name></person-group>. <article-title>Current strategy for staging and treatment: the BCLC update and future prospects</article-title>. <source>Semin Liver Dis</source>. <year>2010</year>;<volume>30</volume>(<issue>1</issue>):<fpage>61</fpage>-<lpage>74</lpage>. doi:<pub-id pub-id-type="doi">10.1055/s-0030-1247133</pub-id><?supplied-pmid 20175034?><pub-id pub-id-type="pmid">20175034</pub-id></mixed-citation>
              </ref>
              <ref id="zoi230944r4">
                <label>4</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Llovet</surname><given-names>JM</given-names></string-name>, <string-name><surname>Villanueva</surname><given-names>A</given-names></string-name>, <string-name><surname>Marrero</surname><given-names>JA</given-names></string-name>, <etal/>; <collab>AASLD Panel of Experts on Trial Design in HCC</collab></person-group>. <article-title>Trial design and endpoints in hepatocellular carcinoma: AASLD consensus conference</article-title>. <source>Hepatology</source>. <year>2021</year>;<volume>73</volume>(<issue>suppl 1</issue>):<fpage>158</fpage>-<lpage>191</lpage>. doi:<pub-id pub-id-type="doi">10.1002/hep.31327</pub-id><?supplied-pmid 32430997?><pub-id pub-id-type="pmid">32430997</pub-id></mixed-citation>
              </ref>
              <ref id="zoi230944r5">
                <label>5</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Kumari</surname><given-names>P</given-names></string-name>, <string-name><surname>Dang</surname><given-names>S</given-names></string-name></person-group>. <article-title>Anti-cancer potential of some commonly used drugs</article-title>. <source>Curr Pharm Des</source>. <year>2021</year>;<volume>27</volume>(<issue>45</issue>):<fpage>4530</fpage>-<lpage>4538</lpage>. doi:<pub-id pub-id-type="doi">10.2174/1381612827666210622104821</pub-id><?supplied-pmid 34161206?><pub-id pub-id-type="pmid">34161206</pub-id></mixed-citation>
              </ref>
              <ref id="zoi230944r6">
                <label>6</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Kelvin</surname><given-names>AS</given-names></string-name>, <string-name><surname>Mitchell</surname><given-names>ID</given-names></string-name>, <string-name><surname>White</surname><given-names>DJ</given-names></string-name></person-group>. <article-title>General and genetic toxicology of paroxetine</article-title>. <source>Acta Psychiatr Scand Suppl</source>. <year>1989</year>;<volume>350</volume>:<fpage>34</fpage>-<lpage>36</lpage>. doi:<pub-id pub-id-type="doi">10.1111/j.1600-0447.1989.tb07166.x</pub-id><?supplied-pmid 2530782?><pub-id pub-id-type="pmid">2530782</pub-id></mixed-citation>
              </ref>
              <ref id="zoi230944r7">
                <label>7</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Bendele</surname><given-names>RA</given-names></string-name>, <string-name><surname>Adams</surname><given-names>ER</given-names></string-name>, <string-name><surname>Hoffman</surname><given-names>WP</given-names></string-name>, <string-name><surname>Gries</surname><given-names>CL</given-names></string-name>, <string-name><surname>Morton</surname><given-names>DM</given-names></string-name></person-group>. <article-title>Carcinogenicity studies of fluoxetine hydrochloride in rats and mice</article-title>. <source>Cancer Res</source>. <year>1992</year>;<volume>52</volume>(<issue>24</issue>):<fpage>6931</fpage>-<lpage>6935</lpage>.<?supplied-pmid 1458482?><pub-id pub-id-type="pmid">1458482</pub-id></mixed-citation>
              </ref>
              <ref id="zoi230944r8">
                <label>8</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Mun</surname><given-names>AR</given-names></string-name>, <string-name><surname>Lee</surname><given-names>SJ</given-names></string-name>, <string-name><surname>Kim</surname><given-names>GB</given-names></string-name>, <string-name><surname>Kang</surname><given-names>HS</given-names></string-name>, <string-name><surname>Kim</surname><given-names>JS</given-names></string-name>, <string-name><surname>Kim</surname><given-names>SJ</given-names></string-name></person-group>. <article-title>Fluoxetine-induced apoptosis in hepatocellular carcinoma cells</article-title>. <source>Anticancer Res</source>. <year>2013</year>;<volume>33</volume>(<issue>9</issue>):<fpage>3691</fpage>-<lpage>3697</lpage>.<?supplied-pmid 24023297?><pub-id pub-id-type="pmid">24023297</pub-id></mixed-citation>
              </ref>
              <ref id="zoi230944r9">
                <label>9</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Chen</surname><given-names>S</given-names></string-name>, <string-name><surname>Xuan</surname><given-names>J</given-names></string-name>, <string-name><surname>Wan</surname><given-names>L</given-names></string-name>, <etal/></person-group>. <article-title>Sertraline, an antidepressant, induces apoptosis in hepatic cells through the mitogen-activated protein kinase pathway</article-title>. <source>Toxicol Sci</source>. <year>2014</year>;<volume>137</volume>(<issue>2</issue>):<fpage>404</fpage>-<lpage>415</lpage>. doi:<pub-id pub-id-type="doi">10.1093/toxsci/kft254</pub-id><?supplied-pmid 24194395?><pub-id pub-id-type="pmid">24194395</pub-id></mixed-citation>
              </ref>
              <ref id="zoi230944r10">
                <label>10</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Hsu</surname><given-names>LC</given-names></string-name>, <string-name><surname>Tu</surname><given-names>HF</given-names></string-name>, <string-name><surname>Hsu</surname><given-names>FT</given-names></string-name>, <string-name><surname>Yueh</surname><given-names>PF</given-names></string-name>, <string-name><surname>Chiang</surname><given-names>IT</given-names></string-name></person-group>. <article-title>Beneficial effect of fluoxetine on anti-tumor progression on hepatocellular carcinoma and non-small cell lung cancer bearing animal model</article-title>. <source>Biomed Pharmacother</source>. <year>2020</year>;<volume>126</volume>:<elocation-id>110054</elocation-id>. doi:<pub-id pub-id-type="doi">10.1016/j.biopha.2020.110054</pub-id><?supplied-pmid 32145588?><pub-id pub-id-type="pmid">32145588</pub-id></mixed-citation>
              </ref>
              <ref id="zoi230944r11">
                <label>11</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Yang</surname><given-names>DK</given-names></string-name>, <string-name><surname>Kim</surname><given-names>SJ</given-names></string-name></person-group>. <article-title>Desipramine induces apoptosis in hepatocellular carcinoma cells</article-title>. <source>Oncol Rep</source>. <year>2017</year>;<volume>38</volume>(<issue>2</issue>):<fpage>1029</fpage>-<lpage>1034</lpage>. doi:<pub-id pub-id-type="doi">10.3892/or.2017.5723</pub-id><?supplied-pmid 28627696?><pub-id pub-id-type="pmid">28627696</pub-id></mixed-citation>
              </ref>
              <ref id="zoi230944r12">
                <label>12</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Cordero</surname><given-names>MD</given-names></string-name>, <string-name><surname>Sánchez-Alcázar</surname><given-names>JA</given-names></string-name>, <string-name><surname>Bautista-Ferrufino</surname><given-names>MR</given-names></string-name>, <etal/></person-group>. <article-title>Acute oxidant damage promoted on cancer cells by amitriptyline in comparison with some common chemotherapeutic drugs</article-title>. <source>Anticancer Drugs</source>. <year>2010</year>;<volume>21</volume>(<issue>10</issue>):<fpage>932</fpage>-<lpage>944</lpage>. doi:<pub-id pub-id-type="doi">10.1097/CAD.0b013e32833ed5f7</pub-id><?supplied-pmid 20847644?><pub-id pub-id-type="pmid">20847644</pub-id></mixed-citation>
              </ref>
              <ref id="zoi230944r13">
                <label>13</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Chen</surname><given-names>VC</given-names></string-name>, <string-name><surname>Lin</surname><given-names>CF</given-names></string-name>, <string-name><surname>Hsieh</surname><given-names>YH</given-names></string-name>, <etal/></person-group>. <article-title>Hepatocellular carcinoma and antidepressants: a nationwide population-based study</article-title>. <source>Oncotarget</source>. <year>2017</year>;<volume>8</volume>(<issue>18</issue>):<fpage>30464</fpage>-<lpage>30470</lpage>. doi:<pub-id pub-id-type="doi">10.18632/oncotarget.12826</pub-id><?supplied-pmid 27783998?><pub-id pub-id-type="pmid">27783998</pub-id></mixed-citation>
              </ref>
              <ref id="zoi230944r14">
                <label>14</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Chan</surname><given-names>HL</given-names></string-name>, <string-name><surname>Chiu</surname><given-names>WC</given-names></string-name>, <string-name><surname>Chen</surname><given-names>VC</given-names></string-name>, <etal/></person-group>. <article-title>SSRIs associated with decreased risk of hepatocellular carcinoma: a population-based case-control study</article-title>. <source>Psychooncology</source>. <year>2018</year>;<volume>27</volume>(<issue>1</issue>):<fpage>187</fpage>-<lpage>192</lpage>. doi:<pub-id pub-id-type="doi">10.1002/pon.4493</pub-id><?supplied-pmid 28666060?><pub-id pub-id-type="pmid">28666060</pub-id></mixed-citation>
              </ref>
              <ref id="zoi230944r15">
                <label>15</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Kao</surname><given-names>WH</given-names></string-name>, <string-name><surname>Hong</surname><given-names>JH</given-names></string-name>, <string-name><surname>See</surname><given-names>LC</given-names></string-name>, <etal/></person-group>. <article-title>Validity of cancer diagnosis in the National Health Insurance database compared with the linked National Cancer Registry in Taiwan</article-title>. <source>Pharmacoepidemiol Drug Saf</source>. <year>2018</year>;<volume>27</volume>(<issue>10</issue>):<fpage>1060</fpage>-<lpage>1066</lpage>. doi:<pub-id pub-id-type="doi">10.1002/pds.4267</pub-id><?supplied-pmid 28815803?><pub-id pub-id-type="pmid">28815803</pub-id></mixed-citation>
              </ref>
              <ref id="zoi230944r16">
                <label>16</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Wu</surname><given-names>CS</given-names></string-name>, <string-name><surname>Lai</surname><given-names>MS</given-names></string-name>, <string-name><surname>Gau</surname><given-names>SS</given-names></string-name>, <string-name><surname>Wang</surname><given-names>SC</given-names></string-name>, <string-name><surname>Tsai</surname><given-names>HJ</given-names></string-name></person-group>. <article-title>Concordance between patient self-reports and claims data on clinical diagnoses, medication use, and health system utilization in Taiwan</article-title>. <source>PLoS One</source>. <year>2014</year>;<volume>9</volume>(<issue>12</issue>):<elocation-id>e112257</elocation-id>. doi:<pub-id pub-id-type="doi">10.1371/journal.pone.0112257</pub-id><?supplied-pmid 25464005?><pub-id pub-id-type="pmid">25464005</pub-id></mixed-citation>
              </ref>
              <ref id="zoi230944r17">
                <label>17</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Grimes</surname><given-names>DA</given-names></string-name>, <string-name><surname>Schulz</surname><given-names>KF</given-names></string-name></person-group>. <article-title>Bias and causal associations in observational research</article-title>. <source>Lancet</source>. <year>2002</year>;<volume>359</volume>(<issue>9302</issue>):<fpage>248</fpage>-<lpage>252</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S0140-6736(02)07451-2</pub-id><?supplied-pmid 11812579?><pub-id pub-id-type="pmid">11812579</pub-id></mixed-citation>
              </ref>
              <ref id="zoi230944r18">
                <label>18</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Fisher</surname><given-names>LD</given-names></string-name>, <string-name><surname>Lin</surname><given-names>DY</given-names></string-name></person-group>. <article-title>Time-dependent covariates in the Cox proportional-hazards regression model</article-title>. <source>Annu Rev Public Health</source>. <year>1999</year>;<volume>20</volume>:<fpage>145</fpage>-<lpage>157</lpage>. doi:<pub-id pub-id-type="doi">10.1146/annurev.publhealth.20.1.145</pub-id><?supplied-pmid 10352854?><pub-id pub-id-type="pmid">10352854</pub-id></mixed-citation>
              </ref>
              <ref id="zoi230944r19">
                <label>19</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Chubak</surname><given-names>J</given-names></string-name>, <string-name><surname>Boudreau</surname><given-names>DM</given-names></string-name>, <string-name><surname>Wirtz</surname><given-names>HS</given-names></string-name>, <string-name><surname>McKnight</surname><given-names>B</given-names></string-name>, <string-name><surname>Weiss</surname><given-names>NS</given-names></string-name></person-group>. <article-title>Threats to validity of nonrandomized studies of postdiagnosis exposures on cancer recurrence and survival</article-title>. <source>J Natl Cancer Inst</source>. <year>2013</year>;<volume>105</volume>(<issue>19</issue>):<fpage>1456</fpage>-<lpage>1462</lpage>. doi:<pub-id pub-id-type="doi">10.1093/jnci/djt211</pub-id><?supplied-pmid 23940288?><pub-id pub-id-type="pmid">23940288</pub-id></mixed-citation>
              </ref>
              <ref id="zoi230944r20">
                <label>20</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Thrift</surname><given-names>AP</given-names></string-name>, <string-name><surname>Natarajan</surname><given-names>Y</given-names></string-name>, <string-name><surname>Liu</surname><given-names>Y</given-names></string-name>, <string-name><surname>El-Serag</surname><given-names>HB</given-names></string-name></person-group>. <article-title>Statin use after diagnosis of hepatocellular carcinoma is associated with decreased mortality</article-title>. <source>Clin Gastroenterol Hepatol</source>. <year>2019</year>;<volume>17</volume>(<issue>10</issue>):<fpage>2117</fpage>-<lpage>2125.e3</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.cgh.2018.12.046</pub-id><?supplied-pmid 30625400?><pub-id pub-id-type="pmid">30625400</pub-id></mixed-citation>
              </ref>
              <ref id="zoi230944r21">
                <label>21</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Sun</surname><given-names>Y</given-names></string-name>, <string-name><surname>Vedsted</surname><given-names>P</given-names></string-name>, <string-name><surname>Fenger-Grøn</surname><given-names>M</given-names></string-name>, <etal/></person-group>. <article-title>Cancer mortality in people treated with antidepressants before cancer diagnosis: a population based cohort study</article-title>. <source>PLoS One</source>. <year>2015</year>;<volume>10</volume>(<issue>9</issue>):<elocation-id>e0138134</elocation-id>. doi:<pub-id pub-id-type="doi">10.1371/journal.pone.0138134</pub-id><?supplied-pmid 26367120?><pub-id pub-id-type="pmid">26367120</pub-id></mixed-citation>
              </ref>
              <ref id="zoi230944r22">
                <label>22</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Schisterman</surname><given-names>EF</given-names></string-name>, <string-name><surname>Cole</surname><given-names>SR</given-names></string-name>, <string-name><surname>Platt</surname><given-names>RW</given-names></string-name></person-group>. <article-title>Overadjustment bias and unnecessary adjustment in epidemiologic studies</article-title>. <source>Epidemiology</source>. <year>2009</year>;<volume>20</volume>(<issue>4</issue>):<fpage>488</fpage>-<lpage>495</lpage>. doi:<pub-id pub-id-type="doi">10.1097/EDE.0b013e3181a819a1</pub-id><?supplied-pmid 19525685?><pub-id pub-id-type="pmid">19525685</pub-id></mixed-citation>
              </ref>
              <ref id="zoi230944r23">
                <label>23</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Glasheen</surname><given-names>WP</given-names></string-name>, <string-name><surname>Cordier</surname><given-names>T</given-names></string-name>, <string-name><surname>Gumpina</surname><given-names>R</given-names></string-name>, <string-name><surname>Haugh</surname><given-names>G</given-names></string-name>, <string-name><surname>Davis</surname><given-names>J</given-names></string-name>, <string-name><surname>Renda</surname><given-names>A</given-names></string-name></person-group>. <article-title>Charlson comorbidity index: ICD-9 update and ICD-10 translation</article-title>. <source>Am Health Drug Benefits</source>. <year>2019</year>;<volume>12</volume>(<issue>4</issue>):<fpage>188</fpage>-<lpage>197</lpage>.<?supplied-pmid 31428236?><pub-id pub-id-type="pmid">31428236</pub-id></mixed-citation>
              </ref>
              <ref id="zoi230944r24">
                <label>24</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Burcu</surname><given-names>M</given-names></string-name>, <string-name><surname>Zito</surname><given-names>JM</given-names></string-name>, <string-name><surname>Safer</surname><given-names>DJ</given-names></string-name>, <etal/></person-group>. <article-title>Association of antidepressant medications with incident type 2 diabetes among Medicaid-insured youths</article-title>. <source>JAMA Pediatr</source>. <year>2017</year>;<volume>171</volume>(<issue>12</issue>):<fpage>1200</fpage>-<lpage>1207</lpage>. doi:<pub-id pub-id-type="doi">10.1001/jamapediatrics.2017.2896</pub-id><?supplied-pmid 29049533?><pub-id pub-id-type="pmid">29049533</pub-id></mixed-citation>
              </ref>
              <ref id="zoi230944r25">
                <label>25</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Bansal</surname><given-names>N</given-names></string-name>, <string-name><surname>Hudda</surname><given-names>M</given-names></string-name>, <string-name><surname>Payne</surname><given-names>RA</given-names></string-name>, <string-name><surname>Smith</surname><given-names>DJ</given-names></string-name>, <string-name><surname>Kessler</surname><given-names>D</given-names></string-name>, <string-name><surname>Wiles</surname><given-names>N</given-names></string-name></person-group>. <article-title>Antidepressant use and risk of adverse outcomes: population-based cohort study</article-title>. <source>BJPsych Open</source>. <year>2022</year>;<volume>8</volume>(<issue>5</issue>):<elocation-id>e164</elocation-id>. doi:<pub-id pub-id-type="doi">10.1192/bjo.2022.563</pub-id><?supplied-pmid 36097725?><pub-id pub-id-type="pmid">36097725</pub-id></mixed-citation>
              </ref>
              <ref id="zoi230944r26">
                <label>26</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Lisinski</surname><given-names>A</given-names></string-name>, <string-name><surname>Hieronymus</surname><given-names>F</given-names></string-name>, <string-name><surname>Eriksson</surname><given-names>E</given-names></string-name>, <string-name><surname>Wallerstedt</surname><given-names>SM</given-names></string-name></person-group>. <article-title>Low SSRI dosing in clinical practice-a register-based longitudinal study</article-title>. <source>Acta Psychiatr Scand</source>. <year>2021</year>;<volume>143</volume>(<issue>5</issue>):<fpage>434</fpage>-<lpage>443</lpage>. doi:<pub-id pub-id-type="doi">10.1111/acps.13275</pub-id><?supplied-pmid 33404081?><pub-id pub-id-type="pmid">33404081</pub-id></mixed-citation>
              </ref>
              <ref id="zoi230944r27">
                <label>27</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Benjamini</surname><given-names>Y</given-names></string-name>, <string-name><surname>Hochberg</surname><given-names>Y</given-names></string-name></person-group>. <article-title>Controlling the false discovery rate: a practical and powerful approach to multiple testing</article-title>. <source>J R Stat Soc Series B Stat Methodol</source>. <year>1995</year>;<volume>57</volume>:<fpage>289</fpage>-<lpage>300</lpage>. doi:<pub-id pub-id-type="doi">10.1111/j.2517-6161.1995.tb02031.x</pub-id></mixed-citation>
              </ref>
              <ref id="zoi230944r28">
                <label>28</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Gibson</surname><given-names>JE</given-names></string-name>, <string-name><surname>Hubbard</surname><given-names>RB</given-names></string-name>, <string-name><surname>Smith</surname><given-names>CJ</given-names></string-name>, <string-name><surname>Tata</surname><given-names>LJ</given-names></string-name>, <string-name><surname>Britton</surname><given-names>JR</given-names></string-name>, <string-name><surname>Fogarty</surname><given-names>AW</given-names></string-name></person-group>. <article-title>Use of self-controlled analytical techniques to assess the association between use of prescription medications and the risk of motor vehicle crashes</article-title>. <source>Am J Epidemiol</source>. <year>2009</year>;<volume>169</volume>(<issue>6</issue>):<fpage>761</fpage>-<lpage>768</lpage>. doi:<pub-id pub-id-type="doi">10.1093/aje/kwn364</pub-id><?supplied-pmid 19181876?><pub-id pub-id-type="pmid">19181876</pub-id></mixed-citation>
              </ref>
              <ref id="zoi230944r29">
                <label>29</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Ostuzzi</surname><given-names>G</given-names></string-name>, <string-name><surname>Matcham</surname><given-names>F</given-names></string-name>, <string-name><surname>Dauchy</surname><given-names>S</given-names></string-name>, <string-name><surname>Barbui</surname><given-names>C</given-names></string-name>, <string-name><surname>Hotopf</surname><given-names>M</given-names></string-name></person-group>. <article-title>Antidepressants for the treatment of depression in people with cancer</article-title>. <source>Cochrane Database Syst Rev</source>. <year>2018</year>;<volume>4</volume>(<issue>4</issue>):<elocation-id>CD011006</elocation-id>. doi:<pub-id pub-id-type="doi">10.1002/14651858.CD011006.pub3</pub-id><?supplied-pmid 29683474?><pub-id pub-id-type="pmid">29683474</pub-id></mixed-citation>
              </ref>
              <ref id="zoi230944r30">
                <label>30</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Shoval</surname><given-names>G</given-names></string-name>, <string-name><surname>Balicer</surname><given-names>RD</given-names></string-name>, <string-name><surname>Feldman</surname><given-names>B</given-names></string-name>, <etal/></person-group>. <article-title>Adherence to antidepressant medications is associated with reduced premature mortality in patients with cancer: a nationwide cohort study</article-title>. <source>Depress Anxiety</source>. <year>2019</year>;<volume>36</volume>(<issue>10</issue>):<fpage>921</fpage>-<lpage>929</lpage>. doi:<pub-id pub-id-type="doi">10.1002/da.22938</pub-id><?supplied-pmid 31332883?><pub-id pub-id-type="pmid">31332883</pub-id></mixed-citation>
              </ref>
              <ref id="zoi230944r31">
                <label>31</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Chilmonczyk</surname><given-names>Z</given-names></string-name>, <string-name><surname>Bojarski</surname><given-names>AJ</given-names></string-name>, <string-name><surname>Pilc</surname><given-names>A</given-names></string-name>, <string-name><surname>Sylte</surname><given-names>I</given-names></string-name></person-group>. <article-title>Serotonin transporter and receptor ligands with antidepressant activity as neuroprotective and proapoptotic agents</article-title>. <source>Pharmacol Rep</source>. <year>2017</year>;<volume>69</volume>(<issue>3</issue>):<fpage>469</fpage>-<lpage>478</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.pharep.2017.01.011</pub-id><?supplied-pmid 28324844?><pub-id pub-id-type="pmid">28324844</pub-id></mixed-citation>
              </ref>
              <ref id="zoi230944r32">
                <label>32</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Zhang</surname><given-names>H</given-names></string-name>, <string-name><surname>Xu</surname><given-names>H</given-names></string-name>, <string-name><surname>Tang</surname><given-names>Q</given-names></string-name>, <string-name><surname>Bi</surname><given-names>F</given-names></string-name></person-group>. <article-title>The selective serotonin reuptake inhibitors enhance the cytotoxicity of sorafenib in hepatocellular carcinoma cells</article-title>. <source>Anticancer Drugs</source>. <year>2021</year>;<volume>32</volume>(<issue>8</issue>):<fpage>793</fpage>-<lpage>801</lpage>. doi:<pub-id pub-id-type="doi">10.1097/CAD.0000000000001067</pub-id><?supplied-pmid 33675613?><pub-id pub-id-type="pmid">33675613</pub-id></mixed-citation>
              </ref>
              <ref id="zoi230944r33">
                <label>33</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Koch</surname><given-names>JM</given-names></string-name>, <string-name><surname>Kell</surname><given-names>S</given-names></string-name>, <string-name><surname>Aldenhoff</surname><given-names>JB</given-names></string-name></person-group>. <article-title>Differential effects of fluoxetine and imipramine on the phosphorylation of the transcription factor CREB and cell-viability</article-title>. <source>J Psychiatr Res</source>. <year>2003</year>;<volume>37</volume>(<issue>1</issue>):<fpage>53</fpage>-<lpage>59</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S0022-3956(02)00061-4</pub-id><?supplied-pmid 12482470?><pub-id pub-id-type="pmid">12482470</pub-id></mixed-citation>
              </ref>
              <ref id="zoi230944r34">
                <label>34</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Peer</surname><given-names>D</given-names></string-name>, <string-name><surname>Dekel</surname><given-names>Y</given-names></string-name>, <string-name><surname>Melikhov</surname><given-names>D</given-names></string-name>, <string-name><surname>Margalit</surname><given-names>R</given-names></string-name></person-group>. <article-title>Fluoxetine inhibits multidrug resistance extrusion pumps and enhances responses to chemotherapy in syngeneic and in human xenograft mouse tumor models</article-title>. <source>Cancer Res</source>. <year>2004</year>;<volume>64</volume>(<issue>20</issue>):<fpage>7562</fpage>-<lpage>7569</lpage>. doi:<pub-id pub-id-type="doi">10.1158/0008-5472.CAN-03-4046</pub-id><?supplied-pmid 15492283?><pub-id pub-id-type="pmid">15492283</pub-id></mixed-citation>
              </ref>
              <ref id="zoi230944r35">
                <label>35</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Zingone</surname><given-names>A</given-names></string-name>, <string-name><surname>Brown</surname><given-names>D</given-names></string-name>, <string-name><surname>Bowman</surname><given-names>ED</given-names></string-name>, <etal/></person-group>. <article-title>Relationship between anti-depressant use and lung cancer survival</article-title>. <source>Cancer Treat Res Commun</source>. <year>2017</year>;<volume>10</volume>:<fpage>33</fpage>-<lpage>39</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.ctarc.2017.01.001</pub-id><?supplied-pmid 28944316?><pub-id pub-id-type="pmid">28944316</pub-id></mixed-citation>
              </ref>
              <ref id="zoi230944r36">
                <label>36</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Boursi</surname><given-names>B</given-names></string-name>, <string-name><surname>Lurie</surname><given-names>I</given-names></string-name>, <string-name><surname>Haynes</surname><given-names>K</given-names></string-name>, <string-name><surname>Mamtani</surname><given-names>R</given-names></string-name>, <string-name><surname>Yang</surname><given-names>YX</given-names></string-name></person-group>. <article-title>Chronic therapy with selective serotonin reuptake inhibitors and survival in newly diagnosed cancer patients</article-title>. <source>Eur J Cancer Care (Engl)</source>. <year>2018</year>;<volume>27</volume>(<issue>1</issue>):<fpage>27</fpage>. doi:<pub-id pub-id-type="doi">10.1111/ecc.12666</pub-id><?supplied-pmid 28252230?><pub-id pub-id-type="pmid">28252230</pub-id></mixed-citation>
              </ref>
              <ref id="zoi230944r37">
                <label>37</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Savitz</surname><given-names>DA</given-names></string-name>, <string-name><surname>Barón</surname><given-names>AE</given-names></string-name></person-group>. <article-title>Estimating and correcting for confounder misclassification</article-title>. <source>Am J Epidemiol</source>. <year>1989</year>;<volume>129</volume>(<issue>5</issue>):<fpage>1062</fpage>-<lpage>1071</lpage>. doi:<pub-id pub-id-type="doi">10.1093/oxfordjournals.aje.a115210</pub-id><?supplied-pmid 2705426?><pub-id pub-id-type="pmid">2705426</pub-id></mixed-citation>
              </ref>
              <ref id="zoi230944r38">
                <label>38</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Shao</surname><given-names>YY</given-names></string-name>, <string-name><surname>Wang</surname><given-names>SY</given-names></string-name>, <string-name><surname>Lin</surname><given-names>SM</given-names></string-name>; <collab>Diagnosis Group</collab>; <collab>Systemic Therapy Group</collab></person-group>. <article-title>Management consensus guideline for hepatocellular carcinoma: 2020 update on surveillance, diagnosis, and systemic treatment by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan</article-title>. <source>J Formos Med Assoc</source>. <year>2021</year>;<volume>120</volume>(<issue>4</issue>):<fpage>1051</fpage>-<lpage>1060</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jfma.2020.10.031</pub-id><?supplied-pmid 33199101?><pub-id pub-id-type="pmid">33199101</pub-id></mixed-citation>
              </ref>
              <ref id="zoi230944r39">
                <label>39</label>
                <mixed-citation publication-type="journal"><person-group><collab>European Association for the Study of the Liver. Electronic address: <email xlink:href="easloffice@easloffice.eu">easloffice@easloffice.eu</email></collab>; <collab>European Association for the Study of the Liver</collab></person-group>. <article-title>EASL clinical practice guidelines: management of hepatocellular carcinoma</article-title>. <source>J Hepatol</source>. <year>2018</year>;<volume>69</volume>(<issue>1</issue>):<fpage>182</fpage>-<lpage>236</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jhep.2018.03.019</pub-id><?supplied-pmid 29628281?><pub-id pub-id-type="pmid">29628281</pub-id></mixed-citation>
              </ref>
            </ref-list>
            <notes notes-type="supplementary-material" id="note-ZOI230944-1">
              <supplementary-material id="note-ZOI230944-1-s" position="float" content-type="local-data">
                <label>Supplement 1.</label>
                <caption>
                  <p><bold>eTable 1.</bold> Association Between Postdiagnosis Antidepressant Use and Mortality in Patients With HCC Using Different Induction Periods</p>
                  <p><bold>eTable 2.</bold> Interaction Between Antidepressant Use and Chemotherapy/Sorafenib for Mortality Risk in Patients With HCC</p>
                </caption>
                <media xlink:href="jamanetwopen-e2332579-s001.pdf">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
              <supplementary-material position="float" content-type="local-data">
                <label>Supplement 2.</label>
                <caption>
                  <p>
Data Sharing Statement
</p>
                </caption>
                <media xlink:href="jamanetwopen-e2332579-s002.pdf">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
            </notes>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
